Search Results
Your search for The ASCO Post matches 139 pages
Showing 101 - 139Boosted Radiation Dose May Make Some Pancreatic Cancers Resectable
Because of their location, cancers on the pancreas often invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult—sometimes impossible....
Abdominal Blood Clots May Indicate Undiagnosed Cancer
New research published by Søgaard et al in Blood found that blood clots in the abdominal veins might be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. Clotting and Cancer Risk Compared to...
Two Studies Highlight Benefit of Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Cancer
Two studies from researchers at Johns Hopkins Kimmel Cancer Center add to preliminary evidence that high-dose radiation treatment, or stereotactic body radiotherapy, appears to be safe and as effective as standard radiation treatment for certain patients with locally advanced pancreatic cancer....
FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...
Weak Sunlight Exposure May Be a Risk Factor in Pancreatic Cancer
Researchers at University of California San Diego School of Medicine recently found that pancreatic cancer rates are highest in countries with the least amount of sunlight. These findings were published by Garland et al in The Journal of Steroid Biochemistry and Molecular Biology. “If...
AACR 2015: Metformin Use May Not Improve Pancreatic Cancer Survival
Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma in a retrospective cohort study presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract LB-183). “The diabetes drug metformin is being used in some cancer treatment...
AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers
Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...
Study Shows Targeting Cancer Cell ‘Cloak’ Could Benefit Drug Delivery
Cancer cells can cloak themselves within tumors by hiding behind a dense layer of cellular stroma. According to a new study by the Translational Genomics Research Institute (TGen), drugs that target and strip away the stroma would pave the way for other drugs to reach the cancerous cells within the ...
Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions
Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...
Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors
Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...
ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors
A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...
Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers
The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...
Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin
Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium (Abstract 234). The primary analysis ...
Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost
A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...
Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...
FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme Therapeutics is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and...
ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors
In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...
Genome-Wide Association Study Finds New Genetic Risk Markers in Pancreatic Cancer
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...
Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy
The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III trial reported at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona (Abstract...
Gene Mutation Found for Aggressive Form of Pancreatic Cancer
Researchers have identified a mutated gene common to adenosquamous carcinoma tumors, the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer. The findings by Liu et al are published in Nature Medicine. Pancreatic cancer is the fourth leading...
Supportive Tumor Tissue Surrounding Cancer Cells Hinders Pancreatic Cancer Progression, Preclinical Study Reports
Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center reported in the journal Cancer Cell. “This supportive tissue that’s...
Surgical Resection Is Underutilized in Patients With Early-Stage Pancreatic Cancer, Study Finds
Despite the benefits of surgery for early-stage pancreatic cancer, it remains underutilized for patients with this deadly disease, according to a new national analysis of trends and outcomes. Physician-scientists at University Hospitals (UH) Case Medical Center and Case Western Reserve University...
Study Finds CT Scans Predict Chemotherapy Response in Pancreatic Cancer
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research published in the Journal of Clinical Investigation by Koay et al, the scans also reflect how well chemotherapy will penetrate the tumor,...
Novel Cancer Vaccine Shows Promise in Ovarian Cancer and Mesothelioma
A novel approach to cancer immunotherapy may provide a new and cost-effective strategy against ovarian cancer and mesothelioma. In a study published in the Journal of Hematology & Oncology, Yuan et al reported that a fusion protein engineered to combine a molecule targeting a tumor-cell-surface ...
Researchers Identify Biomarker for Noncancerous Pancreatic Cysts
Researchers at the Indiana University School of Medicine have discovered a highly accurate, noninvasive test to identify benign pancreatic cysts, which could spare patients the cost and risk of surveillance or potentially dangerous surgical intervention. The findings are reported in the Journal of...
Combination Capecitabine/Temozolomide Appears Highly Effective in Patients With Treatment-Resistant Neuroendocrine Tumors
Interim results from an ongoing phase II clinical trial in patients with various types of advanced neuroendocrine tumors show that a new chemotherapy combination of capecitabine and temozolomide either stalled disease progression or shrank tumors in 95% of patients whose disease worsened after...
Investigational Antibody-Drug Conjugate May Provide New Treatment Option for Pancreatic Cancer Patients
Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October...
Novel Drug Combinations Targeting Pathways Triggered by KRAS May Benefit Patients With Pancreatic Cancer
Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented at the AACR-NCI-EORTC...
Gemcitabine Improves Overall Survival Following Surgery for Pancreatic Cancer
Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in published in the October 9 issue of...
Molecular Marker Predicts Patients Most Likely to Benefit Longest From EGFR Inhibitors
Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...
FDA Approves Nab-Paclitaxel for Late-Stage Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) today expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abraxane) to treat patients with late-stage pancreatic cancer. “Patients with pancreatic cancer are often diagnosed...
Researchers Identify Origin of Inflammation-Driven Pancreatic Cancer
Researchers at Mayo Clinic in Florida have revealed the process by which pancreatitis—chronic inflammation of the pancreas—morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients at risk of pancreatic cancer and to potential drug therapies...
ASCO 2013: For Patients with Metastatic Pancreatic Cancer, Both Treatment and Survival Decrease with Advanced Age
A new study by researchers Fox Chase Cancer Center has identified a disconnect between clinical trials that look at new treatments for metastatic pancreatic cancer and the patient population most likely to be diagnosed with the disease. Clinical trials typically enroll, and base their findings on,...
Molecular Marker from Pancreatic 'Juices' Helps Identify Pancreatic Cancer
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
Novel Drug Combination Showed Antitumor Activity in Patients with Incurable BRCA-deficient Cancers
When given sequentially, two orally available experimental drugs—sapacitabine and seliciclib—worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers, according to phase I data presented at the AACR Annual Meeting 2013, held in Washington, DC, April...
New Metabolite-based Diagnostic Test Could Help Detect Pancreatic Cancer Early
A new diagnostic test that uses a technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection. Researchers examined the utility of metabolomic analysis as a diagnostic method for...
Indiana University Researchers Earn $3.2 Million Grant to Develop, Improve Therapies for Pancreatic Cancer
Two Indiana University researchers have been awarded a multiyear, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States. Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology Research, and Melissa ...
Nab-paclitaxel plus Gemcitabine Demonstrates Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer
Celgene International Sàrl announced on Tuesday that its phase III clinical trial of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abaraxane) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer...
